Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFN-A, Ara-C, and HHT in Early Chronic Phase CML
NCT00003239Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 1998
- Primary completion
- Oct 2001
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of homoharringtonine in chronic myelogenous leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 1998; status: completed.
02
Drugs
homoharringtonine
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00003239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003239.